Contact Information: Contact Information: Stephen Feldschuh 212-330-8515 (Chief Operating Officer) Email Contact Diane Meegan 212-330-8512 (Investor Relations) Email Contact.
Daxor Corporation Files Methods Patent for Blood Optimization Method
| Source: Daxor Corp.
NEW YORK, NY -- (MARKET WIRE) -- February 12, 2007 -- Daxor Corporation (AMEX : DXR ), a medical
instrumentation and biotechnology company, today announced it has filed for
a patent for its Blood Optimization Program.
The Company has developed a program which enables patients undergoing
elective surgery to enter surgery with a normal amount of blood and to have
additional blood of their own available during the operative and
post-operative period. The methodology includes use of the Company's
patented BVA-100 blood volume analyzer, which enables the total amount of
blood in the human body to be measured with an accuracy of within 98%. The
methodology also incorporates the use of blood stimulants such as Epoietin
Alfa, which is manufactured by the Amgen Corporation, and the use of frozen
blood bank technology.
Utilization of these techniques can significantly reduce the incidence of
patients entering surgery in a blood depleted state. The standard tests
used to detect anemia, such as hematocrit or hemoglobin, are only accurate
if the patient has a normal blood volume. Many patients, however, have a
decreased blood volume which masks the true extent of their anemia. Women
normally have 18% fewer red blood cells than men of equal height and
weight. They are, therefore, significantly more vulnerable to needing a
transfusion and have a higher incidence of complications from transfusions.
Utilization of one's own blood avoids problems including infections which
cannot be detected by the standard screening methods, as well as
transfusion reactions which may occur because blood is never completely
cross matched between a donor and a recipient. Another problem that
studies have shown is that refrigerated blood, available for a maximum of
42 days, undergoes significant deterioration within 20 to 30 days. Frozen
blood, which is thawed within 24 to 72 hours of actual use, shows minimal
negative changes. Specially prepared frozen blood can be stored for up to
10 years.
A common method of obtaining blood within 1 to 4 weeks prior to its use
usually does not permit enough time for the patient to replenish the lost
blood. The Blood Optimization Program, because of its freezing technology,
enables blood to be obtained well before surgery, with adequate time for
the patient to replenish the donated blood. Individuals who are at
potential risk for requiring surgery, such as patients with significant
cardiac disease or orthopedic disabilities, can benefit from this type of
program. Another group of patients who could benefit are patients with
potential high risk pregnancies. At the present time the Company plans to
license its methodology to various hospitals.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
www.Daxor.com.